Alvaro J. Alencar

Alvaro J. Alencar

Hematology
1475 Northwest 12th Avenue
Floor 2
Miami, FL 33136

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications

Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors.

Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors.

Journal: Cancer discovery
Published: February 05, 2026

Zanubrutinib for Immunoglobulin A Vasculitis With Monoclonal Gammopathy.

Zanubrutinib for Immunoglobulin A Vasculitis With Monoclonal Gammopathy.

Journal: JAMA dermatology
Published: January 07, 2026

Digitally engaging participants in cancer clinical trials: Design and pilot of the Alliance Participant Engagement Portal (PEP).

Digitally engaging participants in cancer clinical trials: Design and pilot of the Alliance Participant Engagement Portal (PEP).

Journal: JNCI cancer spectrum
Published: December 10, 2025

A phase I/II Study of Duvelisib plus Venetoclax in Patients with Relapsed/Refractory CLL/SLL or Richter Transformation.

A phase I/II Study of Duvelisib plus Venetoclax in Patients with Relapsed/Refractory CLL/SLL or Richter Transformation.

Journal: Blood advances
Published: November 04, 2025

A phase 1/2 study of duvelisib plus venetoclax in patients with relapsed/refractory CLL/SLL or Richter transformation.

A phase 1/2 study of duvelisib plus venetoclax in patients with relapsed/refractory CLL/SLL or Richter transformation.

Journal: Blood advances
Published: November 04, 2025

Immunodeficiency-associated primary CNS lymphomas: An International Primary CNS Lymphoma Collaborative Group (IPCG) Study.

Immunodeficiency-associated primary CNS lymphomas: An International Primary CNS Lymphoma Collaborative Group (IPCG) Study.

Journal: Blood
Published: September 30, 2025

Immunodeficiency-associated primary CNS lymphomas: an International Primary CNS Lymphoma Collaborative Group study.

Immunodeficiency-associated primary CNS lymphomas: an International Primary CNS Lymphoma Collaborative Group study.

Journal: Blood
Published: September 30, 2025

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.

Journal: Blood advances
Published: June 18, 2025

Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN Study.

Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN Study.

Journal: Blood advances
Published: June 18, 2025

A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic Malignancies.

A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic Malignancies.

Journal: Clinical lymphoma, myeloma & leukemia
Published: October 17, 2024

Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial.

Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial.

Journal: The Lancet. Haematology
Published: October 10, 2024

Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia.

Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia.

Journal: Nature reviews. Clinical oncology
Published: October 02, 2024
Showing 1-12 of 41

Last Updated: 09/26/2026